Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2024; 30(25): 3179-3181
Published online Jul 7, 2024. doi: 10.3748/wjg.v30.i25.3179
Scale offers the possibility of identifying adherence to lifestyle interventions in patients with non-alcoholic fatty liver disease
Cen-Qin Liu, Bing Hu
Cen-Qin Liu, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Bing Hu, Department of Gastroenterology and Hepatology/Medical Engineering Integration Laboratory of Digestive Endoscopy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Liu CQ and Hu B co-authored and revised the manuscript; and both authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bing Hu, MD, Editor-in-Chief, Professor, Department of Gastroenterology and Hepatology/Medical Engineering Integration Laboratory of Digestive Endoscopy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. hubing@wchscu.edu.cn
Received: March 18, 2024
Revised: May 27, 2024
Accepted: June 17, 2024
Published online: July 7, 2024
Processing time: 105 Days and 0.2 Hours
Core Tip

Core Tip: Nonalcoholic fatty liver disease is the most common chronic liver disorder and the leading cause of cirrhosis and hepatocellular carcinoma. In this editorial, we aim to highlight the importance of a scale that can evaluate compliance with lifestyle interventions and guide the choice of targeted therapy. However, the universal applicability of the scale and the corresponding personalized treatment need to be carefully considered based on patients’ characteristics and doctors’ expertise.